[{"id":"4ef750b4-3fb6-4689-b95f-2c678d9c99e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04777994","created_at":"2021-03-02T12:52:26.138Z","updated_at":"2025-02-25T14:40:45.849Z","phase":"Phase 1","brief_title":"Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors","source_id_and_acronym":"NCT04777994","lead_sponsor":"AbbVie","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e osunprotafib (ABBV-CLS-484)"],"overall_status":"Recruiting","enrollment":" Enrollment 248","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-14"},{"id":"06b8c716-7a30-4be1-8dc9-8a796ade331e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04417465","created_at":"2022-07-12T13:06:53.108Z","updated_at":"2024-07-02T16:35:26.846Z","phase":"Phase 1","brief_title":"First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors","source_id_and_acronym":"NCT04417465","lead_sponsor":"Calico Life Sciences LLC","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABBV-CLS-579"],"overall_status":"Recruiting","enrollment":" Enrollment 263","initiation":"Initiation: 06/03/2020","start_date":" 06/03/2020","primary_txt":" Primary completion: 08/29/2025","primary_completion_date":" 08/29/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-12-07"}]